Active Management of the Third Stage of Labour: Uterine Tonus Assessment by Midwife vs. Patient Self-administration (UTAMP)

November 23, 2016 updated by: Joyce L. Browne, UMC Utrecht
To determine whether there is a difference in effectiveness of routine uterine tonus assessment (every 15 minutes, for 2 hours) when performed by a midwife or self-administered by a patient on the incidence of postpartum haemorrhage, mean blood loss, and other maternal and neonatal outcomes.

Study Overview

Detailed Description

Rationale: Postpartum haemorrhage (PPH) is the most common cause of maternal death worldwide. The active management of the third stage of labour (AMTSL) is recognized as an effective strategy to prevent morbidity and mortality associated with PPH and reduce blood loss. AMTSL includes the provision of uterotonic drugs, controlled cord traction, delayed cord clamping and cutting, massage of the uterus, and monitoring of the uterine tonus. Although professional guidelines recommend the steps of AMTSL to be performed by health professionals, the reality of health professionals understaffed hospitals in many low- and middle income countries (LMICs) necessitates task-shifting of the final AMTSL component to patients. Yet, whether uterine tonus assessment yields the same effect when performed by patients and midwives has not been formally evaluated.

Objective: To determine whether there is a difference in effectiveness of routine uterine tonus assessment (every 15 minutes, for 2 hours) when performed by a midwife or self-administered by a patient on the incidence of postpartum haemorrhage . mean blood loss, and other maternal and neonatal outcomes.

Study design: Randomized intervention study. Study population: Pregnant women admitted in the labour to the Korle Bu Teaching Hospital, Accra, Ghana Intervention: the intervention group will receive uterine tonus assessment every 15 minutes for 2 hours by a midwife, the control group will continue the current practice of self-assessment after patient education with regular monitoring of midwives.

Main study parameters/endpoints: post-partum haemorrhage (>500 ml blood loss), severe postpartum haemorrhage (>1000 ml blood loss), mean blood loss, other maternal and neonatal outcomes.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will receive the standard of midwifery and obstetric care, and will have access to emergency obstetric interventions. All steps of the AMTSL will be performed, with the exemption of the last step of uterine tonus assessment for which women will be randomized to receive the intervention or current practice of care. Risk associated with the intervention are discomfort because of an external assessment. Data will be obtained from record books at the ward. Women will be asked for informed consent prior to participation. This study will be approved by the Ethical en Protocol Review Committee of the University of Ghana Medical School and the Medical Ethical Research Committee of the University Medical Center Utrecht.

Study Type

Interventional

Enrollment (Actual)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Accra, Ghana
        • Korle Bu Teaching Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Be in labor with an expected vaginal delivery, as assessed by the midwives
  • Gestation age ≥ 37 weeks
  • Received antenatal instructions on postnatal uterine tonus assessment
  • Provided informed consent.

Exclusion Criteria:

  • Age <18
  • Elective caesarean delivery
  • Severe anemia (<8g/dL)
  • Placenta praevia
  • Anticipated breech delivery
  • Referred patients who have not received antenatal care (ANC) uterine tonus assessment instructions
  • Multiple Pregnancy
  • Intra uterine fetal death

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Self-assessment of uterine tonus
Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
Uterine tonus assessment by patient every 15 minutes for 2 hours.
Experimental: Midwife uterine tonus assessment
Uterine tonus assessment every 15 minutes for 2 hours by midwive.
Uterine tonus assessment every 15 minutes for 2 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postpartum hemorrhage (>500 ml blood loss)
Time Frame: within 24 hours postpartum
To determine whether there is a difference in effectiveness of routine uterine tonus assessment (every 15 minutes, for 2 hours) to prevent post-partum hemorrhage (≥500 ml blood loss) when performed by a midwife and self-administered by a patient.
within 24 hours postpartum

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean blood loss (in ml)
Time Frame: Within 24 hours postpartum
Within 24 hours postpartum
Severe post-partum hemorrhage
Time Frame: Within 24 hours postpartum
>1000ml blood loss
Within 24 hours postpartum
Use of additional uterotonics
Time Frame: Within 24 hours postpartum
Within 24 hours postpartum
Use of other procedures for management of postpartum hemorrhage
Time Frame: Within 24 hours postpartum
I.e. surgery, manual placenta tissue removal
Within 24 hours postpartum
Late postpartum hemorrhage
Time Frame: From 24 hours and upto one week
Based on readmission
From 24 hours and upto one week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Joyce L Browne, MD, MSc, UMC Utrecht, The Netherlands
  • Principal Investigator: Kerstin D Klipstein-Grobusch, PhD MSc, University Medical Center Utrecht, the Netherlands
  • Principal Investigator: Nelson Damale, MBChB, Korle-Bu Teaching Hospital, Accra, Ghana

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2014

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

August 11, 2014

First Submitted That Met QC Criteria

August 21, 2014

First Posted (Estimate)

August 22, 2014

Study Record Updates

Last Update Posted (Estimate)

November 25, 2016

Last Update Submitted That Met QC Criteria

November 23, 2016

Last Verified

November 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postpartum Hemorrhage

Clinical Trials on Patient self-assessment of uterine tonus

3
Subscribe